{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T21:45:22Z","timestamp":1782683122272,"version":"3.54.5"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,6,28]]},"DOI":"10.7759\/cureus.111669","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T21:39:39Z","timestamp":1782682779000},"source":"Crossref","is-referenced-by-count":0,"title":["Fatal 5-Fluorouracil Toxicity With Hyperammonemic Encephalopathy, Lactic Acidosis, and Pneumatosis Intestinalis Despite Uridine Triacetate Rescue: A Case Report"],"prefix":"10.7759","author":[{"given":"Hadi","family":"Matar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Sembroski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake","family":"Buzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Shewmaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph R","family":"Blunck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1177\/1559325820951367","article-title":"Comparison of 4 screening methods for detecting fluoropyrimidine toxicity risk: identification of the most effective, cost-efficient method to save lives","volume":"18","author":"Capitain O","year":"2020","unstructured":"Capitain O, Seegers V, Metges JP, et al.. Comparison of 4 screening methods for detecting fluoropyrimidine toxicity risk: identification of the most effective, cost-efficient method to save lives. Dose Response. 2020, 18:1559325820951367. 10.1177\/1559325820951367","journal-title":"Dose Response"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00286-7","article-title":"Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data","volume":"16","author":"Meulendijks D","year":"2015","unstructured":"Meulendijks D, Henricks LM, Sonke GS, et al.. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A\/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol. 2015, 16:1639-50. 10.1016\/S1470-2045(15)00286-7","journal-title":"Lancet Oncol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(18)30686-7","article-title":"DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis","volume":"19","author":"Henricks LM","year":"2018","unstructured":"Henricks LM, Lunenburg CA, de Man FM, et al.. DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis. Lancet Oncol. 2018, 19:1459-67. 10.1016\/S1470-2045(18)30686-7","journal-title":"Lancet Oncol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmoldx.2024.05.015","article-title":"DPYD genotyping recommendations: a joint consensus recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium","volume":"26","author":"Pratt VM","year":"2024","unstructured":"Pratt VM, Cavallari LH, Fulmer ML, et al.. DPYD genotyping recommendations: a joint consensus recommendation of the Association for Molecular Pathology, American College of Medical Genetics and Genomics, Clinical Pharmacogenetics Implementation Consortium, College of American Pathologists, Dutch Pharmacogenetics Working Group of the Royal Dutch Pharmacists Association, European Society for Pharmacogenomics and Personalized Therapy, Pharmacogenomics Knowledgebase, and Pharmacogene Variation Consortium. J Mol Diagn. 2024, 26:851-63. 10.1016\/j.jmoldx.2024.05.015","journal-title":"J Mol Diagn"},{"key":"ref5","unstructured":"FDA approves safety labeling changes regarding DPD deficiency for fluorouracil injection products. (2024). Accessed. 2026: https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-safety-labeling-changes-regarding-dpd-def...."},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.1998.12","article-title":"The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate","volume":"77","author":"Arellano M","year":"1998","unstructured":"Arellano M, Malet-Martino M, Martino R, Gires P. The anti-cancer drug 5-fluorouracil is metabolized by the isolated perfused rat liver and in rats into highly toxic fluoroacetate. Br J Cancer. 1998, 77:79-86. 10.1038\/bjc.1998.12","journal-title":"Br J Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.93.24.13699","article-title":"The reaction of fluorocitrate with aconitase and the crystal structure of the enzyme-inhibitor complex","volume":"93","author":"Lauble H","year":"1996","unstructured":"Lauble H, Kennedy MC, Emptage MH, Beinert H, Stout CD. The reaction of fluorocitrate with aconitase and the crystal structure of the enzyme-inhibitor complex. Proc Natl Acad Sci U S A. 1996, 93:13699-703. 10.1073\/pnas.93.24.13699","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-017-3249-1","article-title":"Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia","volume":"79","author":"Nishikawa Y","year":"2017","unstructured":"Nishikawa Y, Funakoshi T, Horimatsu T, et al.. Accumulation of alpha-fluoro-beta-alanine and fluoro mono acetate in a patient with 5-fluorouracil-associated hyperammonemia. Cancer Chemother Pharmacol. 2017, 79:629-33. 10.1007\/s00280-017-3249-1","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1074","article-title":"5-Fluorouracil: mechanisms of action and clinical strategies","volume":"3","author":"Longley DB","year":"2003","unstructured":"Longley DB, Harkin DP, Johnston PG. 5-Fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003, 3:330-8. 10.1038\/nrc1074","journal-title":"Nat Rev Cancer"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2020.01.019","article-title":"5-Fluorouracil-induced hyperammonaemic encephalopathy: a French national survey","volume":"129","author":"Boil\u00e8ve A","year":"2020","unstructured":"Boil\u00e8ve A, Thomas L, Lillo-Le Lou\u00ebt A, et al.. 5-Fluorouracil-induced hyperammonaemic encephalopathy: a French national survey. Eur J Cancer. 2020, 129:32-40. 10.1016\/j.ejca.2020.01.019","journal-title":"Eur J Cancer"},{"key":"ref11","unstructured":"FLUOROURACIL injection, solution. (2025). Accessed. 2026: https:\/\/dailymed.nlm.nih.gov\/dailymed\/drugInfo.cfm?setid=fdee9255-9447-4ae7-951d-b694802b5966."},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1186\/s12876-025-03601-y","article-title":"Investigating neutropenic enterocolitis: a systematic review of case reports and clinical insights","volume":"25","author":"Nematolahi S","year":"2025","unstructured":"Nematolahi S, Amanati A, Vardanjani HM, et al.. Investigating neutropenic enterocolitis: a systematic review of case reports and clinical insights. BMC Gastroenterol. 2025, 25:17. 10.1186\/s12876-025-03601-y","journal-title":"BMC Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-0638","article-title":"FDA approval: uridine triacetate for the treatment of patients following fluorouracil or capecitabine overdose or exhibiting early-onset severe toxicities following administration of these drugs","volume":"22","author":"Ison G","year":"2016","unstructured":"Ison G, Beaver JA, McGuinn WD Jr, et al.. FDA approval: uridine triacetate for the treatment of patients following fluorouracil or capecitabine overdose or exhibiting early-onset severe toxicities following administration of these drugs. Clin Cancer Res. 2016, 22:4545-9. 10.1158\/1078-0432.CCR-16-0638","journal-title":"Clin Cancer Res"},{"key":"ref14","article-title":"Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity","volume":"123","author":"Ma WW","year":"2017","unstructured":"Ma WW, Saif MW, El-Rayes BF, et al.. Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity. Cancer. 2017, 123:345-56.","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.taap.2018.06.012","article-title":"Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency","volume":"353","author":"Garcia RA","year":"2018","unstructured":"Garcia RA, Saydoff JA, Bamat MK, von Borstel RW. Prompt treatment with uridine triacetate improves survival and reduces toxicity due to fluorouracil and capecitabine overdose or dihydropyrimidine dehydrogenase deficiency. Toxicol Appl Pharmacol. 2018, 353:67-73. 10.1016\/j.taap.2018.06.012","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-025-04839-9","article-title":"Potential clinical relevance of rare dihydropyrimidine dehydrogenase genetic variants identified using whole-exome NextGen sequencing in cancer patients with severe fluoropyrimidine toxicity","volume":"95","author":"Cui E","year":"2025","unstructured":"Cui E, Medwid S, Schwarz UI, Kim RB. Potential clinical relevance of rare dihydropyrimidine dehydrogenase genetic variants identified using whole-exome NextGen sequencing in cancer patients with severe fluoropyrimidine toxicity. Cancer Chemother Pharmacol. 2025, 95:121. 10.1007\/s00280-025-04839-9","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djaf357","article-title":"A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer","volume":"118","author":"Boige V","year":"2026","unstructured":"Boige V, Menoret E, Le Teuff G, et al.. A predictive model for life-threatening fluoropyrimidine toxicity based on DPYD sequencing in colorectal cancer. J Natl Cancer Inst. 2026, 118:699-710. 10.1093\/jnci\/djaf357","journal-title":"J Natl Cancer Inst"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1002\/onco.13967","article-title":"Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis","volume":"26","author":"Sharma BB","year":"2021","unstructured":"Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA. Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist. 2021, 26:1008-16. 10.1002\/onco.13967","journal-title":"Oncologist"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/499697-fatal-5-fluorouracil-toxicity-with-hyperammonemic-encephalopathy-lactic-acidosis-and-pneumatosis-intestinalis-despite-uridine-triacetate-rescue-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T21:39:42Z","timestamp":1782682782000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/499697-fatal-5-fluorouracil-toxicity-with-hyperammonemic-encephalopathy-lactic-acidosis-and-pneumatosis-intestinalis-despite-uridine-triacetate-rescue-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,28]]},"references-count":18,"URL":"https:\/\/doi.org\/10.7759\/cureus.111669","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6,28]]}}}